Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology

Presented By: Noemi Reguart, MD, PhD

Speaker Biography: Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona.

Webinar: Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology

Webinar Abstract: Personalized medicine has beomce a paradigm in lung cancer management; ~ 25–30% of advanced lung cancer patients could benefit from a targeted therapy. Several guidelines currently endorse routine genomic testing of several druggable oncogenic biomarkers—EGFR, ALK, ROS1, and BRAF—in new metastatic non-squamous NSCLC patients, while a number of other emerging molecular targets, such as RET and NTRK gene rearrangements, MET exon 14 skipping mutations (METex14), and activating HER2 or KRAS mutations are likely approaching clinical practice.